NCT05037396View on ClinicalTrials.gov

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

CompletedOBSERVATIONAL
Enrollment

9,457

Participants

Timeline

Start Date

March 5, 2020

Primary Completion Date

August 1, 2020

Study Completion Date

August 1, 2020

Conditions
Age-related Macular Degeneration (AMD)
Interventions
DRUG

Brolucizumab

Participants received brolucizumab injection during the index period

Trial Locations (1)

07936-1080

Novartis Investigational site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY